Eltrombopag and Cyclosporine as First-Line Therapy in Patients with Severe Acquired Aplastic Anemia: A Two-part, 5-year, Single-Arm, Multicenter, Open-label, Phase 2 Trial (SOAR)
iLLUMINATE is a randomized, open-label phase 3 study of ibrutinib plus obinutuzumab (n=113) versus chlorambucil plus obinutuzumab (n=116) as first-line therapy for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma. Eligible patients were aged ≥65 years, or